Table 4.
Outcomes according to the obstruction duration and AKI/APN
| Obstruction duration ≤7 days (group 1) | Obstruction duration >7 days (group 2) | |||||||||
| APN−AKI− (n=504) |
APN−AKI+ (n=267) |
APN+AKI− (n=38) |
APN+AKI+ (n=103) |
P value | APN−AKI− (n=413) |
APN−AKI+ (n=188) |
APN+AKI− (n=24) |
APN+AKI+ (n=69) |
P value | |
| Peak CRP (mg/L) | 1.0 (0.4–2.5) | 1.4 (0.7–3.3) | 69.2 (29.0–122.6) | 78.4 (33.5–171.2) | <0.001 | 1.1 (0.4–2.1) | 1.6 (0.9–3.7) | 55.1 (28.6–95.6) | 141.3 (61.0–224.3) | <0.001 |
| Peak SCr (mg/dL) | 0.9 (0.7–1.0) | 1.3 (1.1–1.6) | 0.9 (0.7–1.0) | 1.5 (1.1–1.9) | <0.001 | 0.9 (0.8–1.1) | 1.3 (1.1–1.7) | 0.9 (0.8–1.1) | 1.8 (1.3–2.6) | <0.001 |
| Lowest eGFR (mL/min/1.73 m2)* | 84.4 (72.9–97.9) | 55.1 (44.6–66.4) | 79.1 (68.6–98.4) | 46.2 (32.1–59.7) | <0.001 | 81.1 (69.2–97.0) | 54.9 (41.0–69.1) | 74.2 (58.0–82.7) | 36.9 (25.0–50.7) | <0.001 |
| GFR 30% reduction, n (%) | 21 (4.17) | 48 (18.0) | 6 (15.8) | 25 (24.3) | <0.001 | 32 (7.8) | 50 (26.6) | 0 (0.0) | 23 (33.3) | <0.001 |
| GFR 50% reduction, n (%) | 0 (0.0) | 10 (3.8) | 1 (2.6) | 13 (12.6) | <0.001 | 8 (1.9) | 18 (9.6) | 0 (0.0) | 13 (18.8) | <0.001 |
| Final SCr (mg/dL) | 0.8 (0.7–1.0) | 0.9 (0.8–1.2) | 0.7 (0.6–0.9) | 0.9 (0.7–1.1) | <0.001 | 0.8 (0.7–1.0) | 1.0 (0.8–1.3) | 0.8 (0.7–1.1) | 1.1 (0.8–1.7) | <0.001 |
| Final eGFR (mL/min/1.73 m2)* | 90.5 (75.5–105.8) | 80.3 (63.4–97.6) | 92.0 (81.5–109.4) | 76.7 (60.1–95.8) | <0.001 | 86.0 (73.0–103.2) | 75.8 (53.7–97.8) | 78.0 (64.2–100.2) | 61.1 (38.4–85.4) | <0.001 |
*eGFR was calculated using the Isotope Dilution Mass Spectrometry (IDMS) traceable Modification of Diet in Renal Disease (MDRD) study equation (mL/min/1.73 m2).
AKI, acute kidney injury; APN, acute pyelonephritis; CRP, C reactive protein; eGFR, estimated glomerular filtration rate;GFR, glomerular filtration rate; SCr, serum creatinine.